l General Information |
Product Name | Decernotinib (VX-509) |
General description | Decernotinib (VX-509) is a potent and selective JAK3 inhibitor with Ki of 2.5 nM, >4-fold selectivity over JAK1, JAK2, and TYK2, respectively. |
Synonym | (2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide |
Purity | ≥98.5%(HPLC) | CAS Number | 944842-54-0 |
Formula | C18H19F3N6O | Molecular Weight | 392.38 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Solid |
Solubility(25°C) | DMSO | ≥50mg/ml |
Ethanol | ≥50mg/ml |
Water | Very slightly soluble |
l Biological Information |
Biochem/Physiol
Actions | Decernotinib has been used in trials studying the treatment of Drug Interactions and Rheumatoid Arthritis. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
